Destro 9x8 Apr 2026

Preliminary studies, such as the MEDITREME trial (a related study), showed promising early efficacy, with a six-month progression-free survival rate of 62.5%.

The study aims to enhance antitumor immune responses in treatment-naïve patients (those who have not previously received treatment) with mCRC. Destro 9x8

T-cell activation through "immunogenic cell death" to overcome traditional resistance to immunotherapy in MSS (microsatellite stable) colorectal cancer. 3. Preliminary studies, such as the MEDITREME trial (a

Based on the available search results, the "Destro 9x8" appears to refer to the , an ongoing clinical study in metastatic colorectal cancer (mCRC), often discussed in literature regarding immuno-oncology. Report: CheckMate 9X8 Trial Overview 1. Subject showed promising early efficacy